Precigen PGEN Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

Regeneron PharmaceuticalsREGN

$15.19B—

Allogene TherapeuticsALLO

$0—

AmgenAMGN

$13.42B+79.2%

Nektar TherapeuticsNKTR

$694.16M+280%

FAQ

What is Precigen's cash, cash equivalents, and marketable securities?

Precigen (PGEN) reported cash, cash equivalents, and marketable securities of $49.26M in Q1 2026.

How has Precigen's cash, cash equivalents, and marketable securities changed year-over-year?

Precigen's cash, cash equivalents, and marketable securities decreased by 34.3% year-over-year, from $74.93M to $49.26M.

What is the long-term trend for Precigen's cash, cash equivalents, and marketable securities?

Over 5 years (2020 to 2025), Precigen's cash, cash equivalents, and marketable securities has grown at a 7.7% compound annual growth rate (CAGR), from $48.33M to $70.14M.

What does cash, cash equivalents, and marketable securities mean?

This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.